Physician profile
Russell Bisesi
NPI 1801906797
$17,544.67
in general payments reported to CMS, 2019-2025
22 companies · $2,147 in 2025
The $2,147 reported for 2025 was more than what 95% of Psychiatric/Mental Health, Child & Adolescent (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $315).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,372 · 2022: $2,657 · 2023: $7,062 · 2024: $2,306 · 2025: $2,147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,564 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,025 · Travel and Lodging: $805 · Education: $122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,563.73 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,025.00 |
| Travel and Lodging | $804.92 |
| Education | $121.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $7,088.07 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $2,035.06 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $1,212.92 | 2021-2025 | Rexulti, Abilify Mycite, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $1,166.78 | 2021-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Tris Pharma INC | $914.94 | 2021-2025 | Dyanavel Xr |
| Corium, LLC | $683.95 | 2021-2025 | Azstarys |
| Lundbeck LLC | $658.62 | 2021-2025 | Rexulti |
| Axsome Therapeutics, INC. | $595.86 | 2022-2025 | Auvelity, Sunosi |
| Vanda Pharmaceuticals INC. | $551.15 | 2021-2025 | Fanapt, Hetlioz |
| Supernus Pharmaceuticals, INC. | $491.78 | 2021-2025 | Qelbree, Qelbree |
| Neurocrine Biosciences, INC. | $451.60 | 2021-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $449.34 | 2021-2024 | Trintellix |
| Alkermes, INC. | $374.22 | 2023-2025 | Aristada, Lybalvi |
| Sunovion Pharmaceuticals INC. | $296.96 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $206.02 | 2021-2025 | Invega Sustenna |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $205.27 | 2024-2025 | Cobenfy |
| Ironshore Pharmaceuticals INC. | $41.46 | 2021-2023 | Jornay Pm |
| Vertical Pharmaceuticals, LLC | $30.72 | 2025 | Relexxii |
| Noven Therapeutics, LLC | $24.66 | 2024 | Secuado, Xelstrym |
| Neos Therapeutics, Lp | $23.25 | 2024 | Adzenys Xr-Odt |
| Jazz Pharmaceuticals INC. | $21.81 | 2021 | |
| Idorsia Pharmaceuticals US INC | $20.23 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Russell Bisesi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.